The miR Sentinel Prostate Cancer Test is a standalone liquid biopsy urine test.
Nitin K. Yerram, MD
Advertisement
Yerram is a urologic oncologist at Hackensack University Medical Center in New Jersey.
Articles by Nitin K. Yerram, MD
The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.
The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
